Clark Estates Inc. NY Has $1.78 Million Holdings in Indivior PLC (NASDAQ:INDV)

Key Points

• Clark Estates Inc. reduced its stake in Indivior PLC by 27.6%, selling 71,125 shares during the first quarter, bringing its total ownership to 186,275 shares valued at approximately $1.78 million.
• Analysts have given Indivior a consensus rating of "Buy", with Jefferies Financial Group setting a price target of $20.00, while Craig Hallum raised their target price to $22.00.
• Indivior's stock price opened at $17.28 with a market capitalization of $2.38 billion, reflecting a 12-month performance range between $7.33 and $17.54.

Clark Estates Inc. NY lowered its holdings in Indivior PLC (NASDAQ:INDV - Free Report) by 27.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 186,275 shares of the company's stock after selling 71,125 shares during the period. Clark Estates Inc. NY owned approximately 0.14% of Indivior worth $1,775,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. GF Fund Management CO. LTD. bought a new position in Indivior during the 4th quarter valued at $36,000. Lazard Asset Management LLC acquired a new stake in shares of Indivior in the fourth quarter valued at approximately $57,000. Schaper Benz & Wise Investment Counsel Inc. WI acquired a new stake in shares of Indivior in the first quarter valued at approximately $95,000. Cannon Global Investment Management LLC acquired a new position in Indivior during the 1st quarter valued at about $95,000. Finally, Stifel Financial Corp increased its stake in Indivior by 24.0% during the 4th quarter. Stifel Financial Corp now owns 12,675 shares of the company's stock valued at $158,000 after buying an additional 2,450 shares during the period. Institutional investors and hedge funds own 60.33% of the company's stock.

Indivior Price Performance

NASDAQ INDV traded up $0.85 during trading on Friday, reaching $21.05. The company's stock had a trading volume of 5,588,537 shares, compared to its average volume of 3,499,157. The business has a 50-day moving average price of $14.65 and a 200-day moving average price of $11.83. Indivior PLC has a 1-year low of $7.33 and a 1-year high of $21.09.

Indivior (NASDAQ:INDV - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.51 earnings per share for the quarter, topping analysts' consensus estimates of $0.26 by $0.25. Indivior had a net margin of 6.65% and a negative return on equity of 85.50%. The business had revenue of $302.00 million during the quarter, compared to analysts' expectations of $239.43 million. As a group, equities analysts predict that Indivior PLC will post 1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Craig Hallum raised their target price on shares of Indivior from $15.00 to $22.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Wall Street Zen raised shares of Indivior from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Finally, Jefferies Financial Group started coverage on shares of Indivior in a research report on Tuesday, July 22nd. They issued a "buy" rating and a $20.00 target price on the stock. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average price target of $17.75.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.